. Author manuscript; available in PMC: 2014 Feb 14.

Published in final edited form as: JAMA. 2012 Feb 22;307(8):804–812. doi: 10.1001/jama.2012.169

Table 1. Characteristics of Invasive Pneumococcal Infections Based on the Active Bacterial Core Surveillance System^*.

	Ages 50-59	Age 60-69	Age 70-79	Age ≥ 80
Invasive pneumococcal disease rates (per 100,000 population per year)
Total	19.6	25.9	33.9	60.1
No comorbid or immunocompromising conditions	9.2	13.1	16.2	33.9
≥1 immunocompromising conditions	67.1	58.5	54.1	64.3
≥1 comorbid conditions	39.2	39.2	48.5	97.2
PPSV23 vaccine serotype coverage (%)	73.3%	74.1%	65.8%	62.9%
PCV13 vaccine serotype coverage (%)	48.3%	48.7%	40.8%	40.8%
Disease outcome rates (per 100,000 population per year)
Meningitis	1.4	1.6	1.3	1.3
Mortality	2.1	2.9	3.9	11.9

Source: Active Bacterial Core Surveillance (ABCs) 2007-2008, Centers for Disease Control and Prevention, from all counties in ABCs PPSV23 = pneumococcal polysaccharide vaccine, PCV13 = 13-valent pneumococcal conjugate vaccine

Table 1. Characteristics of Invasive Pneumococcal Infections Based on the Active Bacterial Core Surveillance System*.

Table 1. Characteristics of Invasive Pneumococcal Infections Based on the Active Bacterial Core Surveillance System^*.